Novanta (NOVT) Projected to Post Quarterly Earnings on Tuesday

Novanta (NASDAQ:NOVT) will likely be issuing its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of $0.88 per share and revenue of $260.7220 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 8:00 AM ET.

Novanta Stock Up 5.1%

NOVT stock opened at $146.39 on Tuesday. Novanta has a 52 week low of $98.27 and a 52 week high of $153.20. The company has a quick ratio of 1.54, a current ratio of 2.51 and a debt-to-equity ratio of 0.56. The firm has a 50-day simple moving average of $129.57 and a 200-day simple moving average of $118.92. The stock has a market capitalization of $5.24 billion, a P/E ratio of 99.59 and a beta of 1.62.

Analyst Upgrades and Downgrades

NOVT has been the subject of several research reports. Zacks Research upgraded Novanta from a “strong sell” rating to a “hold” rating in a research note on Friday, January 16th. Weiss Ratings upgraded Novanta from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 20th. Three research analysts have rated the stock with a Hold rating, According to MarketBeat.com, Novanta currently has an average rating of “Hold” and a consensus target price of $133.00.

Insider Buying and Selling

In related news, CFO Robert Buckley sold 1,423 shares of Novanta stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $140.14, for a total transaction of $199,419.22. Following the transaction, the chief financial officer owned 91,034 shares in the company, valued at approximately $12,757,504.76. This trade represents a 1.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Matthijs Glastra sold 7,500 shares of the company’s stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $145.04, for a total value of $1,087,800.00. Following the completion of the sale, the chief executive officer owned 57,367 shares of the company’s stock, valued at approximately $8,320,509.68. The trade was a 11.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 22,923 shares of company stock valued at $3,182,264 over the last 90 days. Company insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Novanta

A number of institutional investors have recently bought and sold shares of the company. Van ECK Associates Corp grew its stake in shares of Novanta by 17.2% in the 3rd quarter. Van ECK Associates Corp now owns 1,627 shares of the technology company’s stock valued at $163,000 after buying an additional 239 shares during the period. Amundi lifted its holdings in Novanta by 1.4% in the third quarter. Amundi now owns 18,287 shares of the technology company’s stock valued at $1,908,000 after acquiring an additional 245 shares during the last quarter. Nicolet Advisory Services LLC grew its position in Novanta by 7.1% in the third quarter. Nicolet Advisory Services LLC now owns 4,046 shares of the technology company’s stock worth $409,000 after acquiring an additional 269 shares during the period. Danske Bank A S acquired a new stake in Novanta during the third quarter worth $40,000. Finally, Tidal Investments LLC raised its position in Novanta by 15.5% in the second quarter. Tidal Investments LLC now owns 4,779 shares of the technology company’s stock valued at $616,000 after purchasing an additional 640 shares during the period. 98.35% of the stock is owned by hedge funds and other institutional investors.

Novanta Company Profile

Novanta, Inc (NASDAQ: NOVT) is a global technology company that designs and manufactures precision components, subsystems and software used in advanced photonics and motion control applications. The company serves customers in the medical device and advanced industrial markets, supplying critical technologies for diagnostics and therapeutic systems, semiconductor and electronics manufacturing, and scientific instrumentation. Novanta’s product portfolio includes laser control modules, optics, beam delivery systems, high-precision motors, actuators, stages, and fluidics solutions designed to meet stringent accuracy and reliability requirements.

Novanta’s Photonics segment delivers laser and energy delivery components that enable minimally invasive surgical procedures and diagnostic imaging.